Risk of skin cancer after neonatal phototherapy : retrospective cohort study by Brewster, David H et al.
Risk of Skin Cancer after Neonatal Phototherapy: Retrospective Cohort Study

David H Brewster,1,2 Janet S Tucker,3  Michael Fleming,1 Carole Morris,1 Diane L Stockton,1 David J Lloyd,4 Sohinee Bhattacharya,5 James WT Chalmers1,2

1Information Services Division, NHS National Services Scotland, Edinburgh, EH12 9EB, UK
2Division of Community Health Sciences, University of Edinburgh, EH8 9AG, UK
3Obstetrics and Gynaecology, Institute of Applied Health Sciences, University of Aberdeen, AB25 2ZD, UK
4Neonatal Unit, Aberdeen Maternity Hospital, NHS Grampian, AB25 2ZD, UK 




Director, Scottish Cancer Registry, Information Services Division, NHS National Services Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, EH12 9EB
Tel: 0044 (0)131 275 6092	Fax: 0044 (0)131 275 7511
E-mail: David.Brewster@nhs.net (​mailto:David.Brewster@nhs.net​)

Keywords: Melanoma, Neonatal jaundice, Phototherapy, Skin neoplasms
Word count (excluding title page, abstract, references and tables): 2659
ABSTRACT

Objective To assess the risk of skin cancer in persons treated with neonatal phototherapy (NNPT) for jaundice
Design Retrospective cohort study
Setting Grampian Region, Scotland, UK
Data source Aberdeen Maternity and Neonatal Databank. NNPT exposure was abstracted from paper records spanning 1976-1990. Follow-up to 31 December 2006 by linkage to cancer registration and mortality records. 
Main outcome measures Incidence ratios, standardised for age, sex, calendar period, and socio-economic position. 
Results After excluding neonatal deaths (n=435), the cohort comprised 77518 persons. 5868 received NNPT, providing 138000 person-years at risk (median follow-up 24 years). Two cases of melanoma occurred in persons exposed to NNPT versus 16 cases in unexposed persons, yielding a standardised incidence ratio of 1.40 (95% confidence interval 0.17 to 5.04, P=0.834). No cases of squamous cell or basal cell carcinoma of skin were observed in exposed persons. 





In common with many other countries, the incidence of skin cancer, both melanoma[1] and non-melanoma,[2] is increasing in Scotland. Increases in incidence of melanoma, in particular, have been observed in children,[3] and in adolescents and young adults.[4] The increase in incidence of skin cancer is commonly assumed to reflect increasing exposure to sunlight.[5] However, it is conceivable that exposure to other factors, such as the use of sun-beds[6-7] may be playing a role in the evolution of present day trends in skin cancer. The development of cutaneous melanoma has been particularly associated with intermittent exposure to high levels of sunlight in childhood.[8] 

Five studies have investigated the potential impact of intensive blue light phototherapy, used to treat neonatal jaundice, on melanocytic naevus count, a risk factor for subsequent development of cutaneous melanoma.[9-14] The results of these studies are inconsistent, but three of them have raised concerns about potential risks of neonatal phototherapy,[10-13] prompting their authors to propose that exposed children should undergo dermatologic surveillance.[10-11] 

To our knowledge, only a single study has examined the risk of skin cancer (specifically invasive melanoma) following neonatal phototherapy.[15] This was a case-control study conducted in Sweden, comprising 30 cases of childhood cutaneous melanoma and 120 matched hospital controls. Exposure status was assessed from medical records. The researchers found that none of the cases had a history of exposure to neonatal phototherapy. In spite of this, they were unable to exclude the possibility of a small increase in risk, in part because the median follow-up time was only 18 years. 

Intensive blue light phototherapy (peak wavelength 450nm) has been widely used for around four decades to prevent and treat unconjugated hyperbilirubinaemia in neonates. Neonatal jaundice is common and only rarely (and mainly in infants with bilirubin levels of >20mg/dl) leads to the serious condition of kernicterus that has mortality in excess of 10% and long-term morbidity in excess of 70%.[16] Most evidence suggests that phototherapy works principally by converting bilirubin to less lipophilic isomers that are excreted more readily in urine and bile, and to a lesser extent by degrading bilirubin to colourless water soluble degradation products that are excreted in urine.[17-18] 






Sources of data and births studied
The study was based on singleton births held in the Aberdeen Maternity and Neonatal Databank (AMND), covering the years of birth 1976-1990. The AMND holds data for all Aberdeen City births from 1949 to the present day, and includes all reproductive events to women resident in a defined geographical area with a relatively stable population.[19-20] From 1976 onwards, the Databank also includes information on high risk women referred for delivery from other parts of northern Scotland.

Neonatal phototherapy came into widespread use in Aberdeen during the early 1970’s. Until the mid-1980’s, the main type of light source was daylight (wavelength 320 to 700 nm, with a spectral peak between 550 and 600 nm. Blue lights (wavelength 320 to 650 nm, spectral peak 420 to 480 nm) were introduced in the mid-1980s, especially for intensive treatment of high serum bilirubins. A single broad spectrum gas discharge (tungsten-halogen) source was acquired in the late 1980s, but is now obsolete. Light sources were always overhead, and all units had a plastic shield which, along with incubator covers in some cases, would be expected to filter out any UV-A (wavelength 320 to 400 nm). 

The AMND did not begin to hold information on neonatal phototherapy until 1992. Until 1979, all phototherapy was administered in the Neonatal Unit and recorded on paper records, although recording was less complete before 1975. After 1979, some phototherapy was administered on postnatal wards, but paper records also exist for these infants. Trained data entry clerks, unaware of the babies’ subsequent medical history, abstracted information on phototherapy from these paper records. This information was then merged with AMND birth records to generate a birth cohort with phototherapy status recorded. 

Since there is a well-established association between socio-economic position (affluence) and risk of cutaneous melanoma,[21] the 1981 census based Carstairs deprivation category[22] was attached to each person’s record, based on postcode of residence at birth. The Carstairs deprivation score is a small area indicator of socio-economic position based on the prevalence measured at the decennial census of four characteristics: overcrowding, male unemployment, social class, and car ownership.

Record linkage and definitions of skin cancer
This cohort was linked by computerized probability matching[23] to national (Scottish) birth registration records, and thence to the national (Scottish) linked database of acute hospital discharge records, cancer registrations, and deaths to generate an anonymous study database. However, because part of the follow-up period pre-dated the era covered by the national linked database, it was also necessary to seek follow-up for vital status by linkage to national (Scottish) mortality records covering the period 1976-1980. It was not deemed necessary to link the cohort to cancer registration records prior to 1981 because the risk of skin cancer in children under the age of five years is negligible.[3] Both the false positive and false negative rates of record linkage by computerised probability matching in Scotland have been estimated to be less than 1%.[24]

The cohort was followed up until the date of development of any skin cancer, the date of death, or 31 December 2006 (the latest year for which cancer registration data were essentially complete at the time of analysis), whichever occurred first. Skin cancers were defined according to the following diagnostic codes: invasive melanoma of skin ICD9 172, ICD10 C43; invasive squamous cell carcinoma (SCC) of skin ICD9 173 and ICDO M-805–808, ICD10 C44 and ICDO M-805–808; basal cell carcinoma (BCC) ICD9 173 and ICDO M-809, ICD10 C44 and ICDO M-809.

Statistical analysis
Differences in the characteristics of persons exposed to phototherapy compared to those unexposed were assessed using the Mann-Whitney U test, the chi-squared test, or the chi-squared test for trend, as appropriate. Expected numbers of melanoma, SCC and BCC for the population exposed to neonatal phototherapy were calculated by applying age-, sex-, deprivation category-, and calendar period-specific rates in the unexposed population to estimates of the person-years at risk in the exposed population. Indirectly standardised incidence ratios (SIRs) were calculated by dividing the observed numbers by the expected numbers of skin cancers for each histological subtype. Exact Poisson 95% confidence intervals (CI) were calculated.

All analyses were performed using Stata version 8.0 (Stata Corporation, College Station, TX, USA), except for the 95% confidence interval for the standardised incidence ratio for BCC, based on a zero count of observed events, which was calculated according to the methods of Liddell[25] and of Silcocks[26] using software from the following website:
http://www.quantitativeskills.com/sisa/statistics/smr.htm (​http:​/​​/​www.quantitativeskills.com​/​sisa​/​statistics​/​smr.htm​) 






After excluding neonatal deaths under 28 days of age (n=435), the cohort comprised 77518 persons. Of these, 5868 received neonatal phototherapy, providing 138000 person-years at risk and a median follow-up period of 24 years. The characteristics of the study population, according to exposure status, are shown in Table 1. There was no statistically significant difference in mothers’ age at delivery (P=0.272). A higher proportion of babies were allocated to the least deprived categories in both arms of the cohort, reflecting the lower than average prevalence of deprivation in Grampian Region, and there was a significant difference in distribution primarily due to a higher proportion of unexposed persons with unknown deprivation category (P<0.001). A significantly higher proportion of babies exposed to phototherapy were born prior to 1986 (P<0.001), male (P<0.001), of shorter gestation (P<0.001), and of lower birth weight (P<0.001).






We found no statistically significant evidence of an excess risk of melanoma or non-melanoma skin cancer among persons exposed to neonatal phototherapy. 

Strengths
Our cohort study has a number of strengths. It was based on a reasonably well-defined study population; although we could have restricted the study to Aberdeen City to make it more truly population-based, we decided in the interests of maximising statistical power to include the children of high risk mothers referred for delivery to the tertiary Aberdeen Maternity Hospital from outside the city boundaries. It seems unlikely that children of high risk women should have a higher or lower risk of skin cancer. We deliberately excluded children of multiple pregnancies because both multiple pregnancies and skin cancer occur more commonly in persons of higher socio-economic position. A further strength of our study is that exposure data were collected from medical records, and independently of the ascertainment of outcome. Scottish Cancer Registry data are believed to be reasonably complete for melanoma[27] and for non-melanoma skin cancers in the east of Scotland, including Grampian Region.[2] It seems unlikely that ascertainment would vary according to exposure to phototherapy. Finally, our study was focussed on the ultimate outcome of interest (skin neoplasia) rather than intermediate outcomes (such as melanocytic naevus count).

Limitations
The main weakness of our study is the limited statistical power. The size of our study population was limited by the availability of historic neonatal phototherapy data, and it was not feasible to stratify results by gestational age or duration of phototherapy. The follow-up period is necessarily limited because neonatal phototherapy has only been in widespread use since the early 1970’s. Finally the absolute risk of all types of skin cancer is relatively low in persons under the age of 30 years,[4] the oldest attained age among members of the study cohort. Although limited statistical power means that we cannot exclude an effect of neonatal phototherapy on risk of subsequent skin cancer, one of our aims was to rule out a substantive risk, and the results of our study should be considered alongside the results of other studies (see below). 

Although we were able to standardise our results to take some account of socio-economic position, we did not have access to information on other potential confounding variables such as skin type, and lifetime exposure to UV radiation. It would be difficult to capture reliable information on some of these variables retrospectively due to recall bias, and it seems unlikely that they would, in any case, be related to exposure to neonatal phototherapy. 

While it is possible that some members of the cohort may have emigrated from Scotland and are therefore lost to follow-up, we anticipate that the proportion of emigrations from the cohort will be low and unlikely to vary by exposure status. 

Although a study from the west of Scotland has shown that there may be a tendency to over-diagnose melanoma in children,[28] most of the cases of melanoma arising in our study cohort were diagnosed in young adulthood (median age at diagnosis 24.3 years, range 15-29 years). In any case, diagnostic misclassification seems unlikely to be related to exposure to neonatal phototherapy.

Comparison with other studies




Table 4 summarises some of the theoretical reasons for concern about a potential carcinogenic effect of neonatal phototherapy, although many of these are based on observations from animal studies with uncertain relevance to humans. 

Conclusions
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What is already known on this topic?
	Six studies have investigated the potential impact of intensive blue light phototherapy, used to treat neonatal jaundice, on melanocytic naevus count (a risk factor for subsequent development of cutaneous melanoma) or risk of subsequent cutaneous melanoma. 
	The results of these studies are inconsistent, but three of them have raised concerns about potential risks of neonatal phototherapy, prompting their authors to propose that exposed children should undergo dermatologic surveillance.
What this study adds
	We carried out a retrospective cohort study, based on the Aberdeen Maternity and Neonatal Databank, and found no statistically significant evidence of an excess risk of skin cancer following neonatal phototherapy. However, a lack of statistical power and limited period of follow-up means that it is not yet possible to rule out an effect of neonatal phototherapy completely. 
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Table 1 Characteristics of the Study Population According to Exposure Status
Characteristic	Phototherapy(N = 5868)	No Phototherapy(N = 71650)	P value
Mother’s age at delivery - years			0.272
    Median	26	26	
    Interquartile range	22-30	23-29	
    Unknown (number of cases)	0	33	
Carstairs deprivation category – number of cases (%)			<0.001
    1 (least deprived)	2584 (45.8%)	29597 (44.4%)	
    2	1069 (19.0%)	12339 (18.5%)	
    3	876 (15.5%)	10730 (16.1%)	
    4	935 (16.6%)	11804 (17.7%)	
    5 (most deprived)	175 (3.1%)	2239 (3.4%)	
    Unknown	229 (3.9%)	4941 (6.9%)	
Year of birth – number of cases (%)	 	 	<0.001
   1976-1980	2039 (34.8%)	22589 (31.5%)	 
    1981-1985	2215 (37.8%)	22731 (31.7%)	 
    1986-1990	1614 (27.5%)	26330 (36.8%)	 
Gender – number of cases (%)	 	 	<0.001
    Male	3428 (58.4%)	36445 (50.9%)	 
    Female	2439 (41.6%)	35010 (48.9%)	 
    Unknown	1 (0.02%)	195 (0.27%)	 
Gestational age - weeks	 	 	<0.001
    Median	38	40	 
    Interquartile range	35-40	39-41	 
    Unknown (number of cases)	5	118	 
Birth weight – grams	 	 	<0.001
    Median	2980	3360	 
    Interquartile range	2390-3410	3040-3680	 
    Unknown (number of cases)	1	237	 
Table 2 Standardized Incidence Ratios of Skin Cancer by Histological Type among Persons Exposed to Neonatal Phototherapy
Histological Type	Observed No. of Cancers	Expected No. of Cancers	Standardized Incidence Ratio	95% Confidence Interval	P-value
Melanoma	      2	1.43	1.40	0.17 – 5.04	0.834
Squamous cell carcinoma	0	0.00	-	-	-




Table 3 Summary of Previous Studies on the Association Between Exposure to Neonatal Phototherapy (NNPT) and Subsequent Development of Melanocytic Skin Lesions
Author(s), Year of publication, Setting	Outcome studied	Study population	Study findings	Limitations
Berg and Lindelhöf,[15] 1997, Sweden	Skin melanoma	Identified from Swedish Cancer Registry and Swedish Medical Birth Registry. 30 cases of melanoma aged <20 years (range 7-18), born between 1973 and 1992. 120 controls matched for date of birth, hospital, and sex. NNPT exposure ascertained from medical records for those with NNPT-related diagnoses.	No cases of melanoma had received NNPT. 11/120 (9%) controls received NNPT.	Partly dependent on routinely collected data (but believed to be of high quality). Not all records were reviewed. Median follow-up limited to 18 years. Statistical power insufficient to rule out an effect. No information on confounding factors, such as family history of melanoma, skin type, and sun exposure.
Bauer et al,[9] 2004, Germany	Melanocytic naevi	Cross sectional study of 1812 white children aged 2 to 7 years attending day care centres in two cities. Total body naevus count by dermatologic examiners. NNPT exposure ascertained by parental interview.	333/1812 (18%) received NNPT. No evidence of an increased risk of melanocytic naevi associated with NNPT.	Study results reported in a letter, although further details of methods available from a previous paper. Exposure data dependent on parental recall. Not clear that dermatologic examiners were blinded to exposure status.
Matichard et al,[10] 2006, France	Melanocytic naevi	Described as ‘case-control prospective study’, although cases and controls were selected on the basis of exposure rather than outcome. ‘Cases’ were 18 children aged 8 to 9 years exposed to NNPT, retrospectively identified by review of consecutive neonatal medical records. ‘Controls’ were 40 unexposed children aged 8 to 9 years recruited consecutively from a public school in the same geographic area. Total body naevus count assessed by a single observer.  	Melanocytic naevus count, when limited to naevi 2 to 5 mm in diameter, was statistically significantly associated with prior exposure to intensive NNPT.	Exposed and unexposed children were selected by different mechanisms (although matched for age, geographic area and skin type). Not clear that dermatologic examiner was blinded to exposure status. Association only present when restricted to naevi 2 to 5 mm in diameter. Limited statistical power. No information provided on family history of melanoma (but fairly comprehensive information on other potential confounding factors).
Csoma et al,[11-12] 2007, Hungary	Common melanocytic naevi and clinically atypical naevi	Unselected population of 747 students aged 14 to 18 years from two secondary schools. NNPT exposure ascertained by questionnaire (in consultation with parents), but was preceded by whole body examination (excluding scalp and anogenital area).	Among the 44.6% of children previously exposed to NNPT, the researchers found higher numbers of common melanocytic naevi, and a statistically significantly higher prevalence of atypical naevi.	Only limited details of the study design and methods were provided in two letters. Exposure data dependent on parental recall. No information provided on confounding factors, such as family history of melanoma, skin type, and sun exposure.
Csoma et al,[13] 2008, Hungary	Common melanocytic naevi and clinically atypical naevi	11 monozygotic twin pairs in which one twin received NNPT and the other did not. 	Twins exposed to NNPT were found to have a statistically significantly higher number of common and atypical naevi.	Only limited details of study design and methods were provided in a letter. Wide age range of participants (6-30 years). Not clear that dermatologic examiner was blinded to exposure status. Limited statistical power.











Table 4 Some Theoretical Reasons for Concern about the Risk of Skin Cancer Following Neonatal Phototherapy
Observation	Comment
Neonatal phototherapy may spill over into UV-A region.[12]Blue light can generate reactive oxygen species,[30-31] and induce DNA damage,[31] especially in the presence of bilirubin.[33]Of the visible light spectrum, the blue spectral band (420 to 500 nm) is mainly responsible for DNA breaks and sister chromatid exchanges in cultured Chinese hamster cells.[34]Arc welding, which has a high blue light effective radiance,[35] is a significant risk factor for uveal melanoma.[36]Exposure to wavelengths in the visible spectrum induces melanoma in a backcross hybrid of the small tropical fish of the genus Xiphophorus, bred to have only one tumour suppressor gene.[38] Exposure of uveal melanoma cell lines to blue light increases cell proliferation, both in vitro,[39] and (in an animal model) in vivo.[40]Prolonged exposure to blue light has induced uveal melanoma in a rat.[42]	Properly shielded fluorescent lamps emit little UV-A and blue light-emitting-diode (LED) lights none at all.[29]Visible light is much less effective than UV-A at inducing DNA single strand breaks.[32]Animal model.Sunlight also has high blue light effective radiance,[35] but has not been associated with uveal melanoma.[37]Animal model.Blue light has also been shown to inhibit the growth of B16 melanoma cell lines.[41]Single case report in an animal model also in receipt of a compound with calcium channel blocking properties that may have inhibited apoptosis.
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